Wave Life Sciences (WVE) EBITDA Margin (2016 - 2025)
Historic EBITDA Margin for Wave Life Sciences (WVE) over the last 11 years, with Q2 2025 value amounting to 579.68%.
- Wave Life Sciences' EBITDA Margin fell 4120700.0% to 579.68% in Q2 2025 from the same period last year, while for Sep 2025 it was 682.43%, marking a year-over-year decrease of 4499200.0%. This contributed to the annual value of 89.7% for FY2024, which is 388600.0% down from last year.
- Latest data reveals that Wave Life Sciences reported EBITDA Margin of 579.68% as of Q2 2025, which was down 4120700.0% from 510.3% recorded in Q1 2025.
- Over the past 5 years, Wave Life Sciences' EBITDA Margin peaked at 14.67% during Q3 2023, and registered a low of 13712.28% during Q3 2022.
- In the last 5 years, Wave Life Sciences' EBITDA Margin had a median value of 510.3% in 2025 and averaged 2379.74%.
- Per our database at Business Quant, Wave Life Sciences' EBITDA Margin tumbled by -136951500bps in 2022 and then soared by 137269500bps in 2023.
- Quarter analysis of 5 years shows Wave Life Sciences' EBITDA Margin stood at 1975.18% in 2021, then plummeted by -78bps to 3520.18% in 2022, then surged by 98bps to 55.75% in 2023, then tumbled by -201bps to 167.6% in 2024, then plummeted by -246bps to 579.68% in 2025.
- Its EBITDA Margin stands at 579.68% for Q2 2025, versus 510.3% for Q1 2025 and 167.6% for Q2 2024.